Theriva presents preclinical data for VCN-12 oncolytic adenovirus at ESGCT congress

Theriva Biologics, Inc.

VCN-12, derived from VCN-01, armed with transgenes to improve tumor lysis, stroma degradation, and antitumor immune response.
Presentation at ESGCT 2025 in Seville, Spain on October 8, 2025, by co-founder Dr. Ramón Alemany.
Preclinical study published in Human Gene Therapy shows intracranial VCN-01 administration feasible for brain tumor treatment.
Study concludes findings provide strong rationale for VCN-01 development as therapy for brain tumors.
No financial guidance or material changes to business operations announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.